Literature DB >> 20222933

Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease.

S Hanneken1, A Rütten, S M Pasternack, S Eigelshoven, L El Shabrawi-Caelen, J Wenzel, M Braun-Falco, T Ruzicka, M M Nöthen, R Kruse, R C Betz.   

Abstract

BACKGROUND: Galli-Galli disease (GGD) is a rare genodermatosis. Its clinical presentation is identical to that of Dowling-Degos disease (DDD), but the presence of the histopathological feature of acantholysis in GGD is thought to distinguish the two disorders. Mutations in the keratin 5 gene (KRT5) have been identified in the majority of patients with DDD and in a small number of patients with GGD.
OBJECTIVES: To provide further support for the hypothesis that GGD is merely a variant of DDD, and to examine whether acantholysis is genuinely rare in DDD or rather a common but under-reported histological feature of DDD.
METHODS: We conducted the first systematic mutational investigation of patients with GGD and re-examined the histopathology of patients previously assigned a diagnosis of DDD. For the mutational investigation, KRT5 was sequenced in seven unrelated patients with clinically and histopathologically confirmed GGD. In addition, the histopathological findings of six patients with DDD were re-evaluated.
RESULTS: The mutation c.418dupA was found in five patients with GGD. The typical histopathological features of GGD were identified in six patients who had previously been assigned a diagnosis of DDD.
CONCLUSIONS: We found further evidence to suggest that GGD is indeed a variant of DDD and not a distinct disease entity. Two facts in particular support this conclusion: the same KRT5 mutation was found in patients with GGD and in patients with DDD, and acantholysis seems to be present in a large number of patients who had previously been assigned a diagnosis of DDD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20222933     DOI: 10.1111/j.1365-2133.2010.09741.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease.

Authors:  F Buket Basmanav; Ana-Maria Oprisoreanu; Sandra M Pasternack; Holger Thiele; Günter Fritz; Jörg Wenzel; Leopold Größer; Maria Wehner; Sabrina Wolf; Christina Fagerberg; Anette Bygum; Janine Altmüller; Arno Rütten; Laurent Parmentier; Laila El Shabrawi-Caelen; Christian Hafner; Peter Nürnberg; Roland Kruse; Susanne Schoch; Sandra Hanneken; Regina C Betz
Journal:  Am J Hum Genet       Date:  2014-01-02       Impact factor: 11.025

2.  [Galli-Galli disease. Clinical and histopathological investigation using a case series of 18 patients].

Authors:  S Hanneken; A Rütten; S Eigelshoven; M Braun-Falco; S M Pasternack; T Ruzicka; M M Nöthen; R C Betz; R Kruse
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

3.  [Hereditary pigmentary disorders].

Authors:  K Giehl; M Braun-Falco
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

4.  Mutations in POGLUT1 in Galli-Galli/Dowling-Degos disease.

Authors:  N J Wilson; C Cole; K Kroboth; W N Hunter; J A Mann; W H I McLean; K Kernland Lang; H Beltraminelli; R A Sabroe; N Tiffin; G J Sobey; L Borradori; E Simpson; F J D Smith
Journal:  Br J Dermatol       Date:  2016-09-24       Impact factor: 9.302

5.  Acitretin therapy for Galli-Galli disease.

Authors:  Chandler W Rundle; Solveig Ophaug; Eric L Simpson
Journal:  JAAD Case Rep       Date:  2020-04-30

6.  Exacerbation of Galli-Galli Disease Following Dialysis Treatment: A Case Report and Review of Aggravating Factors.

Authors:  Tejas P Joshi; Sally Shaver; Jaime Tschen
Journal:  Cureus       Date:  2021-06-02

7.  The First Report of KRT5 Mutation Underlying Acantholytic Dowling-Degos Disease with Mottled Hypopigmentation in an Indian Family.

Authors:  Shyam Verma; Sandra M Pasternack; Arno Rütten; Thomas Ruzicka; Regina C Betz; Sandra Hanneken
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

8.  Heterozygous frameshift mutation in keratin 5 in a family with Galli-Galli disease.

Authors:  A K Reisenauer; S V Wordingham; J York; E W J Kokkonen; W H I Mclean; N J Wilson; F J D Smith
Journal:  Br J Dermatol       Date:  2014-06       Impact factor: 9.302

9.  Non‑invasive proteome‑wide quantification of skin barrier‑related proteins using label‑free LC‑MS/MS analysis.

Authors:  Mengting Liu; Jing Zhang; Yaochi Wang; Cong Xin; Jie Ma; Shuangjun Xu; Xiaomeng Wang; Jinping Gao; Xuejun Zhang; Sen Yang
Journal:  Mol Med Rep       Date:  2020-03-11       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.